Top

Published in:

01-02-2016 | Original Article

In situ dendritic cell vaccination for the treatment of glioma and literature review

Authors: Ming Li, Shuangyin Han, Xiwen Shi

Published in: Tumor Biology | Issue 2/2016

Abstract

Glioma is one of the greatest threats to human health, and invasive growth of glioma is its major cause of death. Inhibiting or blocking angiogenesis can effectively inhibit tumor growth and metastasis or dramatically reduce the size of the original lesion. Therefore, anti-angiogenic therapy has currently become the most promising treatment strategy for glioma. Although dendritic cells (DCs) used in DC-based immunotherapy are loaded with tumor-associated antigens, the anti-tumor immune response is effectively stimulated in cytotoxic specific T lymphocytes (CTLs), thereby achieving targeted killing of tumor cells without harming surrounding normal cells. This makes it a highly promising new form of therapy. This article reviews the existing evidence regarding in situ DC vaccination for the treatment of glioma and puts forward hypotheses regarding patient, tumor, and technical factors and warrant further investigation.

Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1(1):27–31.CrossRefPubMed

Kerbel RS. A cancer therapy resistant to resistance. Nature. 1997;390(27):335–6.CrossRefPubMed

Gille J. Antiangiogenic cancer therapies get their act together: current developments and future prospects of growth factor- and growth factor receptor-targeted approaches. Exp Dermatol. 2006;15(3):175–86.CrossRefPubMed

Juratli TA, Schackert G, Krex D. Current status of local therapy in malignant gliomas—a clinical review of three selected approaches. Pharmacol Ther. 2013;139(3):341–58.CrossRefPubMed

Fan M, Liu Y, Xia F, Wang Z, Huang Y, Li J, et al. Increased expression of EphA2 and E-N cadherin switch in primary hepatocellular carcinoma. Tumori. 2013;99(6):689–96.PubMed

Russo S, Incerti M, Tognolini M, Castelli R, Pala D, Hassan-Mohamed I, et al. Synthesis and structure-activity relationships of amino acid conjugates of cholanic acid as antagonists of the EphA2 receptor. Molecules. 2013;18(10):13043–60.CrossRefPubMed

Chen H, Yuan B, Zheng Z, Liu Z, Wang S, Liu YA. Novel vaccine containing EphA2 epitope and LIGHT plasmid induces robust cellular immunity against glioma U251 cells. Cell Immunol. 2011;272(1):102–6.CrossRefPubMed

Alho I, Costa L, Bicho M, Coelho C. Low molecular weight protein tyrosine phosphatase isoforms regulate breast cancer cells migration through a RhoA dependent mechanism. PLoS One. 2013;8(9):e76307.CrossRefPubMedPubMedCentral

Strimpakos A, Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G. The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab. Clin Colorectal Cancer. 2013;12(4):267–74.CrossRefPubMed

10.

Hegde M, Corder A, Chow KK, Mukherjee M, Ashoori A, Kew Y. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther. 2013;21(11):2087–101.CrossRefPubMedCentral

11.

Mantripragada K, Khurshid H. Targeting genomic alterations in squamous cell lung cancer. Front Oncol. 2013;3(8):195.PubMedPubMedCentral

12.

Lee HY, Mohammed KA, Goldberg EP, Nasreen N. Arginine-conjugated albumin microspheres inhibits proliferation and migration in lung cancer cells. Am J Cancer Res. 2013;3(3):266–77.PubMedPubMedCentral

13.

Lu XS, Sun W, Ge CY, Zhang WZ, Fan YZ. Contribution of the PI3K/MMPs/Ln-5γ2 and EphA2/FAK/Paxillin signaling pathways to tumor growth and vasculogenic mimicry of gallbladder carcinomas. Int J Oncol. 2013;42(6):2103–15.PubMed

14.

Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nat Rev Cancer. 2006;6(7):559–65.CrossRefPubMed

15.

Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303(5665):1818–22.CrossRefPubMed

16.

Howard KA, Rahbek UL, Liu X. RNA interference in vitro and in vivo using a novel Chitosan/siRNA nanoparticle system. Mol Ther. 2006;14(4):476–84.CrossRefPubMed

17.

Laperchia C, Allegra Mascaro AL, Sacconi L, Andrioli A, Matt A, De Franceschi L, et al. Two-photon microscopy imaging of thy1GFP-M transgenic mice: a novel animal model to investigate brain dendritic cell subsets in vivo. PLoS One. 2013;8(2):e56144.CrossRefPubMedPubMedCentral

18.

Li M, Wang B, Wu Z, Zhang J, Shi X, Han S. A novel recombinant protein of ephrinA1-PE38/GM-CSF activate dendritic cells vaccine in rats with glioma. Tumor Biol. 2015. doi:10.1007/s13277-015-3217-5.

19.

Wang X, Zhao HY, Zhang FC, Sun Y, Xiong ZY, Jiang XB. Dendritic cell-based vaccine for the treatment of malignant glioma: a systematic review. Cancer Invest. 2014;32(9):451–7.CrossRefPubMed

20.

Eyrich M, Rachor J, Schreiber SC, Wölfl M, Schlegel PG. Dendritic cell vaccination in pediatric gliomas: lessons learnt and future perspectives. Front Pediatr 2013;10;1:12.

21.

Li M, Wang B, Wu Z, Zhang J, Shi X, Han S. Treatment of glioma rat models using EphrinA1-PE38/GM-CSF chitosan nanoparticles by in-situ activation of dendritic cells. Tumour Biol (2015).

22.

Kyte JA, Mu L, Aamdal S, Kvalheim G. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther. 2006;13(10):905–18.CrossRefPubMed

23.

Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol. 2011;29(3):330–6.CrossRefPubMed

24.

Holtl L, Rieser C, Papesh C, Ramoner R, Herold M, Klocker H, et al. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol. 1999;161(3):777–82.CrossRefPubMed

25.

Wang H, Su X, Zhang P, Liang J, Wei H, Wan M, et al. Recombinant heat shock protein 65 carrying PADRE and HBV epitopes activates dendritic cells and elicits HBV-specific CTL responses. Vaccine. 2011;29(12):2328–35.CrossRefPubMed

26.

Debenedette MA, Calderhead DM, Tcherepanova IY, Nicolette CA, Healey DG. Potency of mature CD40L RNA electroporated dendritic cells correlates with IL-12 secretion by tracking multifunctional CD8(+)/CD28(+) cytotoxic T-cell responses in vitro. J Immunother. 2011;34(1):45–57.CrossRefPubMed

27.

Gong J, Avigan D, Chen D, Wu Z, Koido S, Kashiwaba M, et al. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc Natl Acad Sci U S A. 2000;97(6):2715–8.CrossRefPubMedPubMedCentral

28.

Szanto A, Balint BL, Nagy ZS, Barta E, Dezso B, Pap A, et al. STAT6 transcription factor is a facilitator of the nuclear receptor PPARgamma-regulated gene expression in macrophages and dendritic cells. Immunity. 2010;33(5):699–712.CrossRefPubMedPubMedCentral

29.

Liu Y, Zhang W, Chan T, Saxena A, Xiang J. Engineered fusion hybrid vaccine of IL-4 gene-modified myeloma and relative mature dendritic cells enhances antitumor immunity. Leuk Res. 2002;26(8):757–63.CrossRefPubMed

30.

Wertel I, Bednarek W, Stachowicz N, Rogala E, Nowicka A, Kotarski J. Phenotype of dendritic cells generated from peripheral blood monocytes of patients with ovarian cancer. Transplant Proc. 2010;42(8):3301–5.CrossRefPubMed

31.

den Brok MH, Sutmuller RP, Nierkens S, Bennink EJ, Frielink C. Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity. Br J Cancer. 2006;95(7):896–905.CrossRef

32.

Martins A, Han J, Kim SO. The multifaceted effects of granulocyte colony-stimulating factor in immunomodulation and potential roles in intestinal immune homeostasis. IUBMB Life. 2010;62(8):611–7.CrossRefPubMedPubMedCentral

33.

Lee JH, Roh MS, Lee YK, Kim MK, Han JY. Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model. Cancer Gene Ther. 2010;17(2):73–9.CrossRefPubMed

34.

Si T, Guo Z, Hao X. Combined cryoablation and GM-CSF treatment for metastatic hormone refractory prostate cancer. J Immunother. 2009;32(1):86–91.CrossRefPubMed

35.

Ward JE, Mcneel DG. GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer. Expert Opin Biol Ther. 2007;7(12):1893–902.CrossRefPubMed

36.

Nemunaitis J. Vaccines in cancer: GVAX, a GM-CSF gene vaccine. Expert Rev Vaccines. 2005;4(3):259–74.CrossRefPubMed

37.

Harzstark AL, Small EJ. Sipuleucel-T for the treatment of prostate cancer. Drugs Today (Barc). 2008;44(4):271–8.CrossRef

Title: In situ dendritic cell vaccination for the treatment of glioma and literature review
Authors: Ming Li
Shuangyin Han
Xiwen Shi
Publication date: 01-02-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 2/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-3958-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2016

Diagnostic and prognostic value of serum thioredoxin and DJ-1 in non-small cell lung carcinoma patients

Influence of the interaction between long noncoding RNAs and hypoxia on tumorigenesis

Association of intercellular adhesion molecule-1 single nucleotide polymorphisms with hepatocellular carcinoma susceptibility and clinicopathologic development

Propensity score-based comparison of hepatic resection and transarterial chemoembolization for patients with advanced hepatocellular carcinoma

Association of the functional BCL-2 rs2279115 genetic variant and small cell lung cancer

Presence of tumour high-endothelial venules is an independent positive prognostic factor and stratifies patients with advanced-stage oral squamous cell carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer